Search details
1.
Modulation of proteasome subunit selectivity of syringolins.
Bioorg Med Chem
; 106: 117733, 2024 May 15.
Article
in English
| MEDLINE | ID: mdl-38704960
2.
Development of small molecule-drug conjugates based on derivatives of natural proteasome inhibitors that exhibit selectivity for PSMA-expressing cancer cells.
Bioorg Med Chem
; 108: 117773, 2024 Jun 03.
Article
in English
| MEDLINE | ID: mdl-38850999
3.
[Multiple myeloma with IgH::MYC and multiple extramedullary lesions].
Rinsho Ketsueki
; 65(3): 147-152, 2024.
Article
in Japanese
| MEDLINE | ID: mdl-38569857
4.
Discovery of Biologically Optimized Polymyxin Derivatives Facilitated by Peptide Scanning and In Situ Screening Chemistry.
J Am Chem Soc
; 145(6): 3665-3681, 2023 02 15.
Article
in English
| MEDLINE | ID: mdl-36708325
5.
Identification of non-neutralizing anti-factor X autoantibodies in three Japanese cases of autoimmune acquired factor X deficiency.
Haemophilia
; 29(2): 555-563, 2023 Mar.
Article
in English
| MEDLINE | ID: mdl-36478471
6.
Crovalimab treatment in patients with paroxysmal nocturnal haemoglobinuria: Long-term results from the phase I/II COMPOSER trial.
Eur J Haematol
; 111(2): 300-310, 2023 Aug.
Article
in English
| MEDLINE | ID: mdl-37321625
7.
Solid-Phase Synthesis of Nannocystin Ax and Its Analogues.
J Org Chem
; 88(15): 11367-11371, 2023 Aug 04.
Article
in English
| MEDLINE | ID: mdl-37466434
8.
Severe Bone Marrow Aplasia Following Macrophage Activation Syndrome in Systemic Lupus Erythematosus.
Tohoku J Exp Med
; 260(4): 301-304, 2023 Aug 11.
Article
in English
| MEDLINE | ID: mdl-37164698
9.
Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes with Donor-Specific Anti-HLA Antibodies against HLA-DP.
Tohoku J Exp Med
; 261(2): 123-127, 2023 Oct 17.
Article
in English
| MEDLINE | ID: mdl-37558420
10.
The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria.
Blood
; 135(12): 912-920, 2020 03 19.
Article
in English
| MEDLINE | ID: mdl-31978221
11.
Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma.
Ann Hematol
; 101(5): 979-989, 2022 May.
Article
in English
| MEDLINE | ID: mdl-35244756
12.
Design, synthesis and conformation-activity relationship analysis of LNA/BNA-type 5'-O-aminoribosyluridine as MraY inhibitors.
Bioorg Med Chem
; 65: 116744, 2022 07 01.
Article
in English
| MEDLINE | ID: mdl-35500521
13.
Synthesis of capuramycin and its analogues via a Ferrier-type I reaction and their biological evaluation.
Bioorg Med Chem
; 73: 117011, 2022 11 01.
Article
in English
| MEDLINE | ID: mdl-36191548
14.
Structural insights into inhibition of lipid I production in bacterial cell wall synthesis.
Nature
; 533(7604): 557-560, 2016 05 26.
Article
in English
| MEDLINE | ID: mdl-27088606
15.
TM5614, an Inhibitor of Plasminogen Activator Inhibitor-1, Exerts an Antitumor Effect on Chronic Myeloid Leukemia.
Tohoku J Exp Med
; 257(3): 211-224, 2022 Jun 25.
Article
in English
| MEDLINE | ID: mdl-35491124
16.
Polythiophene-Doped Resorcinol-Formaldehyde Resin Photocatalysts for Solar-to-Hydrogen Peroxide Energy Conversion.
J Am Chem Soc
; 143(32): 12590-12599, 2021 Aug 18.
Article
in English
| MEDLINE | ID: mdl-34292725
17.
Safety and antitumor activity of acalabrutinib for relapsed/refractory B-cell malignancies: A Japanese phase I study.
Cancer Sci
; 112(6): 2405-2415, 2021 Jun.
Article
in English
| MEDLINE | ID: mdl-33728735
18.
Prophylactic antiviral therapy for hepatitis B virus surface antigen-positive patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy.
Cancer Sci
; 112(5): 1943-1954, 2021 May.
Article
in English
| MEDLINE | ID: mdl-33576088
19.
Efficacy and safety of romiplostim in refractory aplastic anaemia: a Phase II/III, multicentre, open-label study.
Br J Haematol
; 192(1): 190-199, 2021 01.
Article
in English
| MEDLINE | ID: mdl-33152120
20.
Structure, solubility, and permeability relationships in a diverse middle molecule library.
Bioorg Med Chem Lett
; 37: 127847, 2021 04 01.
Article
in English
| MEDLINE | ID: mdl-33571648